

Supplemental Table 1. TaqMan® Gene Expression Assays for Gene Validation\*

Gene	TaqMan® Assay Number
<i>Hoxb13</i>	Mm00433968_m1
<i>Rprm</i> (or Reprimo)	Mm00469773_s1
<i>Mre11a</i>	Mm00450600_m1
<i>Cdk1</i>	Mm00772472_m1
<i>Cdk7</i>	Mm01282896_m1
<i>Myc</i>	Mm00487804_m1
<i>Cxcl5</i>	Mm00436451_g1
<i>Fabp7</i>	Mm00445225_m1
<i>Ctnnb1</i> (or $\beta$ -catenin)	Mm00483039_ml
<i>Pten</i>	Mm00477208_m1
<i>Tesc</i>	Mm00498717_m1
<i>Pthlh</i>	Mm00436057_m1
<i>Mapk11</i>	Mm00440955_m1
<i>Igf1</i>	Mm00439560_m1
<i>Hprt1</i>	Mm00446968_m1
<i>Tfr3</i>	Mm00441941_m1

\*TaqMan® assays were obtained from Life Technologies. Each sample was run in triplicate, according to the manufacturer's protocol.

Supplemental Table 2. Tumor Data Summary for In Vivo Experiment\*

Treatment	Tumor Status at Baseline	N	Gross SI Tumor (Mean ± SEM)	Colon Adenomas (Mean ± SEM)	Colon Microadenomas (Mean ± SEM)	Colon Tumor Volume (mm <sup>3</sup> ) (Mean ± SEM)	Tumor Incidence (%)
Control	All mice	20	49.5 ± 3.93	4.6 ± 0.88	1.0 ± 0.39	7.4 ± 1.20	
	Tumor-bearing	12		6.4 ± 1.17	1.3 ± 0.64	7.4 ± 1.83	
	Tumor-free	8		1.8 ± 0.48	0.6 ± 0.20	7.5 ± 1.11	87.5%
Sulindac	All mice	20	22.7 ± 2.74	3.4 ± 0.85	0.6 ± 0.22	4.1 ± 0.63	
	Tumor-bearing	9		4.8 ± 1.54	0.9 ± 0.45	5.1 ± 0.50	
	Tumor-free	11		2.2 ± 0.51	0.4 ± 0.20	3.2 ± 0.88	90.9%
Atorvastatin	All mice	19	54.3 ± 5.98	3.3 ± 0.77	0.6 ± 0.22	8.5 ± 1.75	
	Tumor-bearing	10		5.4 ± 1.32	1.1 ± 0.37	10.1 ± 2.30	
	Tumor-free	9		1.2 ± 0.49	0 ± 0	5.18 ± 1.68	55.6%
Sul/Atorva	All mice	22	29.2 ± 2.86	2.9 ± 0.48	0.5 ± 0.16	7.8 ± 1.14	
	Tumor-bearing	12		3.7 ± 0.74	0.8 ± 0.22	8.1 ± 0.99	
	Tumor-free	10		1.9 ± 0.48	0.3 ± 0.2	7.3 ± 2.37	70%

\* P values are presented in Figure 2 and 4.

Supplemental Table 3. Effect of Sulindac and/or Atorvastatin on Cell Cycle Analysis in SW480 Cells\*

Treatment	G0/G1 (%)	S (%)	G2/M (%)
DMSO	56.6 ± 0.93	29.8 ± 4.92	10.9 ± 1.19
Sulindac 120 µM	55.8 ± 1.03	32.6 ± 0.52	11.3 ± 0.45
Sulindac 60 µM	55.0 ± 1.27	32.5 ± 0.64	12.1 ± 0.43
Sulindac 30 µM	58.5 ± 1.77	31.7 ± 0.98	11.6 ± 0.61
Atorvastatin 1 µM	57.8 ± 1.69	31.0 ± 0.65	11.4 ± 1.54
Atorvastatin 0.5 µM	60.4 ± 3.67	32.8 ± 3.22	9.4 ± 2.77
Atorvastatin 0.1 µM	58.6 ± 1.59	29.8 ± 0.78	12.8 ± 0.29
Sul/Atorva 120 µM/1 µM	78.0 ± 0.46 <sup>§</sup>	14.5 ± 0.07 <sup>§</sup>	10.2 ± 0.38
Sul/Atorva 120 µM/0.5 µM	69.7 ± 0.43 <sup>§</sup>	21.5 ± 0.72 <sup>§</sup>	11.7 ± 0.23
Sul/Atorva 120 µM/0.1 µM	58.2 ± 0.43	31.9 ± 0.56	11.6 ± 0.50
Sul/Atorva 60 µM/1 µM	76.2 ± 1.10 <sup>Δ</sup>	16.9 ± 0.99 <sup>Δ</sup>	10.7 ± 0.29
Sul/Atorva 60 µM/0.5 µM	69.0 ± 1.38 <sup>Δ</sup>	24.6 ± 1.44 <sup>Δ</sup>	9.4 ± 1.60
Sul/Atorva 60 µM/0.1 µM	68.2 ± 1.91 <sup>Δ</sup>	23.7 ± 1.41 <sup>Δ</sup>	11.6 ± 0.14
Sul/Atorva 30 µM/1 µM	65.5 ± 2.15	31.8 ± 0.80	6.4 ± 1.40
Sul/Atorva 30 µM/0.5 µM	61.4 ± 1.18	30.1 ± 1.74	10.7 ± 1.38
Sul/Atorva 30 µM/0.1 µM	59.9 ± 1.70	28.3 ± 1.42	12.5 ± 0.59

\* Data is shown as Mean ± SEM. N=3 per treatment.

<sup>§</sup> P < 0.004 when compared to those of Sulindac 120 µM.

<sup>Δ</sup> P < 0.004 when compared to those of Sulindac 60 µM.